Results Imminent From Sweden’s Pilot Of Novel Antibiotic Reimbursement Model
If successful, a new Swedish model for reimbursing antibiotics that involves guaranteed minimum annual revenues for companies could be tested on other kinds of products.
You may also be interested in...
A group of EU member states has written to the European Commission saying that an exclusivity voucher scheme intended to stimulate R&D into new antimicrobials will stifle innovation by competitor companies and push up costs for national health systems.
Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”